In this presentation Dr. Dino Prato argues that conventional high‑dose chemotherapy and radiation can paradoxically promote cancer progression by releasing excessive damage‑associated molecular patterns (DAMPs) that activate the TLR4/NF‑κB inflammatory cascade, creating a hostile tumor microenvironment that fuels resistance and metastasis. He proposes an immune‑centric, precision‑oncology approach that uses deep multi‑omics profiling to guide metronomic (low‑dose) chemotherapy and identify patients who would benefit from adjunctive therapies. Central to his argument is the repurposed drug low‑dose naltrexone (LDN), a cheap off‑label opioid antagonist that at sub‑therapeutic doses blocks TLR4, reduces pro‑inflammatory cytokines, modulates opioid growth factor (OGF) signaling to impose a brake on cell proliferation, and may act as a chemosensitizer and angiogenesis inhibitor. Prato emphasizes that LDN is not a cure but can sharpen immune signaling when DAMPs are excessive, provided that precise biomarker testing confirms the right target profile. He stresses the necessity of physician supervision, individualized N‑of‑1 multi‑omics testing, and a balanced therapeutic strategy that avoids the toxicity of maximal chemotherapy while harnessing the immune system’s natural ability to eradicate cancer.
Chapters
What if part of your chemotherapy was actually teaching your cancer to come back stronger with inflammation? Not because the drug was inherently bad or the chemotherapy was off, but because of the wrong selection, too high of a dose and fundamental failure to involve your immune system. So instead it pushes runaway inflammation and a powerful danger signals that allows the cancer to spread. Today I want to show you how a simple off label repurposed drug called low dose naltrexone, very cheap, may help turn down the inflammation fire, pushing cancer towards the right kind of cell death. This is only in specific cases where the data matches and is right for the patient in a unique way and in their unique biology. It's not for everyone. You want to be under care of a doctor anytime you're adding or combining to your care. I'm Dr. Dino Prado. For the last 25 years, my team and I have helped thousands of patients who've already failed some of the top cancer hospitals across the United States. But they still need more answers. So we run deep multiomics, DNA, RNA transcriptomics, immune profiling, thousand plus markers to build an immune centric protocol that's to each patient using the latest technologies from around the world. So today I want to talk to you about something simple and yet powerful that almost no one is really excited about and I think they should be. And how the runaway inflammation from chemotherapy, or the wrong treatment or too much of a good thing can fuel cancer. It's not just what treatment you get, it's the signals that the treatment is sending to your immune system. And in particular, how a repurposed drug called low dose naltrexone may help reduce the wrong signals. The chronic inflammation and the damage associated molecular patterns that are involved that can push cancer in the wrong direction when they're too strong and the signals are off. Let's start simple. When chemotherapy kills cancer cells, those cells break apart and they spill their contents into the surrounding tissue. Think of these tiny molecules going everywhere. These contents are then telling a signal to the immune system. They're called damps. Damage associated molecular patterns, all these tiny molecules. Think of the DAMPS as these little danger signals that are turning on your immune system to find and fight the cancer. ATP spilled cells, uric acid crystals, proteins like HMGB1 and these dams tell the immune system, hey, something's wrong. Here's what they look like. Go kill these cancer cells in a controlled setting. These danger flags are critical. They're critical for the immune system. In fact, in my opinion, they do the entire job. No matter what treatment you do, it's these signals and your immune system that's ultimately going to rid the cancer. They can help trigger the right immune responses. What we call an immunogenic cell death. That's the key of precision oncology and really all the work we do in our algorithms that kind of TR your immune system to fight the cancer, know where it is and find it everywhere in the body. Because your immune system like your natural killer cells, they can go to the bone, it can go to the the brain, it can go to anywhere there's metastases. And it can find the cancer before it has spread into a tumor at a cellular level. That's why immunotherapy is so important. But here's when the problem starts. When we have too high of a dose of chemotherapy or too much radiation or too much now, we start getting inflammation, stress and the immunological response gets fuzzy. You can end up with a damage associated molecular patterns or what we these danger flags plug into receptors of your immune cells. Especially receptors called toll receptors TLR4. And these damps bind to the TLR4. They flip on a powerful inflammatory switch called NF Kappa Beta which drives the release of aggressive cytokines, an aggressive immune response that isn't necessarily healthy. IL1 and IL6 these will grow cancer. That means more chronic inflammation and more tissue damage and more destruction in the tumor microenvironment immun invasion immune cells blocking the part of your immune system needs to kill the cancer, creating resistance. Chemotherapy can be doing two things at once. Killing the cancer and creating an inflammatory storm that may help the cancer cell become more aggressive, resistant and adapt to survival. So I want you to see that that it's not just all good. And that's why I am not a big fan of maximum therapeutic chemotherapy, but metronomic dose which is based on testing. And the right targets that you need is you only need 10 or 15% the dose if you have the right targets. Or you can get right to the tumor with chemo immunoprecision, avoiding all of the toxicity, going to the rest of your tissue and central nervous system and getting too much of an expression of these dams. So instead our goal is to create an immune centric care, keep the cancer kill going, reduce the wrong signals and get your immune system to work in this beautiful concert where it kills cancer cells, releases the damps, more immune system gets recruited, goes after more cancer cells. Because this is what your body does naturally. And here's where low dose naltrexone comes in because it's important low Dose naltrexone is old, it's a generic medication and it's very cheap at standard do say around 50 milligrams. It treats opioid and alcoholic dependence. But in very low doses like 4.5 milligrams or lower, it behaves dramatically different. Because remember everything is dose dependent and has to have the right matching target. So don't just go taking these medications. I'm giving you some background. At low doses, naltrexone shows a paradoxical anti inflammatory effect, pain reduction, which cancer patients like. So oftentimes patients with fibromyalgia or Ms. Or Crohn's will have doctors that use it off label to support that care modulation to the microglia and the immune cells in the brain that drive neuro inflammation and chronic pain. Most importantly it blocks the TLR4. I just talked about the same over response that came from the damage associated molecular patterns that were showing too much inflammatory switches being turned on and those cascades upregulating the low dose naltrexone comes in to help. So when the DAMP markers are present and you can test for them and they're in excess, the drug becomes an excellent choice as an off label adjuvant alongside your other care to shift a bad inflammatory response to a good immune modulatory response. All based on targeting the TLR4. So let's continue with this. When chemotherapy injury occurs and you get damage associated molecular patterns happening and they hit the TLR4 receptors, this activates downstream pathways and turns on inflammation like I just talked about all these cytokines, inflammatory storms. So in plain language we want to shut down these storms so that the immune system can do its work. And evidence in the published data shows that naltrexone in the right right micro doses can block this inflammatory response and calm the immune cells to get back on track. So this is an example of a repurposed drug you don't hear a lot about, doesn't get a lot of popularity like a lot of them and there are so many of them. But I want to give these examples because there's a place for these under the care of a right doctor. Conceptually our immune centric thinking to cancer is so important because if we give too high dose of a chemo or radiation, it creates the wrong storm, the wrong signaling of the damps pouring fuel and inflammation into the cancer so it can spread, spread. But if we can add a low dose naltrexone on the TLR4, kind of think of it as an antagonist it will help turn down the fire, reduce the wrong signals. Think of this forest fire just going crazy and you're trying to put it out with just a hose, when in fact you might need an airplane to drop water on the storm to calm it down so that you can control how the fire burns. People that do control burning of like forestry understand what I'm talking about. You want to control it. And when you control it, you get the right release of the damps and you get an immune immunogenic pattern of cell death. This is the key to cancer. You don't want too much inflammation, you want the right amount of immune response. We're not saying that low dose naltrexone is a magic bullet here at all. In fact it's not. We're saying that it can be helpful and it can sharpen the signal in a way to help our biology better fight cancer when chemo and other treatments have really overdone it or even immunotherapies over pushed inflammation. Low dose naltrexone doesn't just work through the TLR4, it also impacts the opioid growth factors. Now these opioid growth fact, think of it like peptides that your body makes. And its main job is to slow down cell proliferation or cell growth. It's a natural brake pedal on cell growth. And here's the fascinating part. Short term low dose naltrexone temporarily blocks these opioid receptors. Your body responds by both powerfully upregulating OGF receptors and OGFR that can slow down cancer's growth. So studies have shown that low dose naltrexone can reduce tumor burden, decrease angiogenesis. This is that blood supply that gets the T. Cut it off, the powerful picture emerges. Calm the wrong inflammation, strengthen the body's own brake pedal on cell division. That fits beautifully into when a repurposed drug is needed with precision oncology, when the targets are right, another critical point, it can act as a chemosensitizer. Pre clinical work suggests that low dose naltrexone with chemotherapy can lead to greater inhibition of tumor growth, more suppression of the DNA synthesis and angiogenesis to recoup blood supplies, and even less toxicity, including less weight loss in animal studies. Now these haven't proven in humans, but in combination with clinical experience, it can make a difference. As physicians we've seen this. Instead of always pushing for more drugs and higher doses, what we need is the right targets. And that's what precision oncology allows us to do, is get all the right targets. For the chemo, for the on off label, for the integrative, the natural phytotherapeutics, the immune. And when the markers are correct, low dose naltrexone can support and act as a tool, help make the chemotherapy more effective in certain cases, especially when combined with the right precision targets for each patient. So this means less collateral damage potentially and better outcomes for some patients. Long care or better response where they weren't getting a response that was working well. That's the power of precision testing. So you may ask me how do we know if I need low dose naltrexone? It's going to be in the testing because we don't want to just hit or miss. We want the right targets for each patient. That's why you have to work with the right doctors, get the right testing so that you can go after cancer. Remember, we want the immune system to do the work, but we also want to calm the chronic inflammation. And this is where the low dose naltrexone studies help us. We've already seen it in certain cases, help with fibromyalgia, ms, inflammatory bowels and it's been consistent and it dampens inflammation. Well guess what happens when cancer is growing and spreading? We have inflammation so we want to modulate it and get the immune system active. So cancer patients undergoing chemo often living with very high damps, damage associated molecular patterns that are pushing too high. They have sleep disturbances, neuro inflammation and we want to modulate this TLR4. That's when we consider low dose naltrex. It helps us to get the cancer treatment to be more immunocentric because that's what we want the immune system to do the work. We want the dams to be in smaller concentrations to make the immune system work in our favor instead of leading to the progression and spread of the cancer. The healthier your immune system and your nervous system are the better quality of life the patients will have as well. The key to all this starts with N of 1 treatment. We need a custom multi omics to see what all your targets are. Get the right blueprints and when we have that information, we can see how adjuvants like like low dose naltrexone or other repurposed or integrative agents can support care to help patients respond better. It's not a standalone therapy or a cure. In the right blueprint, low dose naltrexone can help provide the right signals for the immune system and support the healing pathways. So this is important. I hope this gave you a better idea of another example of repurposed drugs and how they can make a difference in helping somebody respond better when they have the right targets. I hope this was helpful. And may the Lord bless you on your journey to healing.
